Literature DB >> 3191483

A Gompertzian model of human breast cancer growth.

L Norton1.   

Abstract

The pattern of growth of human breast cancer is important theoretically and clinically. Speer et al. (Cancer Res., 44: 4124-4130, 1984) have recently proposed that all individual tumors initially grow with identical Gompertzian parameters, but subsequently develop kinetic heterogeneity by a random time-dependent process. This concept has elicited interest because it fits clinical data for the survival of untreated patients, for the progression of shadows on serial paired mammograms, and for time-to-relapse following mastectomy. The success of these curve-fits is compelling, and the model has been applied to clinical trials. However, the assumption of uniform nascent growth is not supported by theory or data, and individual cancers have not been shown to follow the complex growth curves predicted by the Speer model. As an alternative, if kinetic heterogeneity is understood to be an intrinsic property of neoplasia, the same three historical data sets are fit well by an unadorned Gompertzian model which is parsimonious and has many other intuitive and empirical advantages. The two models differ significantly in such clinical projections as the estimated duration of silent growth prior to diagnosis and the anticipated optimal chemotherapy schedule postsurgery.

Entities:  

Mesh:

Year:  1988        PMID: 3191483

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  156 in total

Review 1.  Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?

Authors:  Yaacov Richard Lawrence; Deborah T Blumenthal; Diana Matceyevsky; Andrew A Kanner; Felix Bokstein; Benjamin W Corn
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

2.  A delay differential equation model for tumor growth.

Authors:  Minaya Villasana; Ami Radunskaya
Journal:  J Math Biol       Date:  2003-05-15       Impact factor: 2.259

3.  Optimizing dose-dense regimens for early-stage breast cancer.

Authors:  Patrick G Morris; Clifford A Hudis
Journal:  Nat Rev Clin Oncol       Date:  2010-12       Impact factor: 66.675

Review 4.  Mutation and epigenetic molecular clocks in cancer.

Authors:  Darryl Shibata
Journal:  Carcinogenesis       Date:  2010-11-12       Impact factor: 4.944

Review 5.  Adjuvant chemotherapy for primary breast cancer.

Authors:  Monica Fornier; Clifford Hudis
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

6.  Chemotherapy agents: a primer for the interventional radiologist.

Authors:  Frank Mihlon; Charles E Ray; Wells Messersmith
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

7.  A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.

Authors:  Jan Lankelma; Rafael Fernández Luque; Henk Dekker; Jaap van den Berg; Bob Kooi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-18       Impact factor: 2.745

8.  Mathematical Modeling of Tumor-Tumor Distant Interactions Supports a Systemic Control of Tumor Growth.

Authors:  Sebastien Benzekry; Clare Lamont; Dominique Barbolosi; Lynn Hlatky; Philip Hahnfeldt
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

9.  A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression.

Authors:  Kerri-Ann Norton; Michael Wininger; Gyan Bhanot; Shridar Ganesan; Nicola Barnard; Troy Shinbrot
Journal:  J Theor Biol       Date:  2009-12-16       Impact factor: 2.691

Review 10.  [Current developments in use of docetaxel (taxotere) in gynecologic oncology].

Authors:  C Jackisch
Journal:  Med Klin (Munich)       Date:  1998-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.